New pill CTX001 aims to fix iron issues – first human tests begin

NCT ID NCT07577817

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called CTX001 in 72 healthy adults. The goal is to check for side effects and see how the drug affects iron levels in the blood, with or without iron supplements and food. It is a first step toward possibly treating anemia and iron deficiencies in people with chronic kidney disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CTX001 (tablet)

What this could lead to

If successful, this could point toward a new treatment for iron-related problems in conditions like anemia and chronic kidney disease.

What could go wrong

This is a very early Phase 1 trial in only 72 healthy people, so it may not work or be safe in patients. Side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia chronic kidney disease chronic renal failure syndrome Iron Deficiencies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nucleus Network

    RECRUITING

    Melbourne, Victoria, 3004, Australia